NEW YORK, Aug. 7 - Rosetta Inpharmatics and Agilent Technologies said Tuesday that the Max Planck Institutes for Molecular Genetics, Infection Biology, and Molecular Plant Physiology would act as European demonstration sites for the Rosetta Resolver Gene Expression Data Analysis System and Agilent’s DNA Microarray Scanner.
Rosetta Inpharmatics, based in Kirkland, Wash., also said it has launched a satellite customer service operation in Europe, housed at Agilent Technologies' facility in Amsterdam, The Netherlands.
Bill Buffington, vice president and general manager of Agilent Technologies' life sciences division, said the deal with the German research institutes would “allow greater access to the Rosetta Resolver system and Agilent's new open-systems-based DNA Microarray Scanner for prospective users in Europe.”
Financial details of the agreement were not disclosed.
Agilent, based in Palo Alto, Calif., said its new DNA Microarray Scanner scans industry-standard 1-inch by 3-inch glass slides and offers automated 48-slide scanning. Agilent holds exclusive distribution rights to the Rosetta Resolver enterprise bioinformatics system for gene expression data analysis.In May, Merck acquired Rosetta for $620 million in stock, but said that Rosetta would continue to operate the Resolver business as a separate cost center and that the acquisition would not affect the alliance between Rosetta and Agilent.